Ständer S, Yosipovitch G, Legat FJ, et al. - This study was undertaken to investigate the effect of nemolizumab in moderate-to-Severe prurigo nodularis. Researchers performed a 12-week, randomized, double-blind, phase 2 trial of nemolizumab (at a dose of 0.5 mg per kilogram of body weight) administered subcutaneously at baseline, week 4, and week 8, as correlated with placebo, in individuals with moderate-to-severe prurigo nodularis and severe pruritus. A sum of 70 individuals were randomly allocated in a 1:1 ratio to receive nemolizumab (34 patients) or placebo (36). It was demonstrated that nemolizumab produced a greater reduction in pruritus and severity of skin lesions than placebo in individuals with prurigo nodularis but was associated with adverse events. To ascertain the durability and safety of nemolizumab for the treatment of prurigo nodularis, larger and longer trials are required.